By Fineline Cube 
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its exclusive agreement with Adimmune Corporation, effective June 30, 2025. The decision ends their collaboration on distributing quadrivalent seasonal influenza vaccines in mainland China, originally established in February 2023, due to significant changes in market conditions.
Post-Termination Strategy
Post – termination, Clover will no longer handle the vaccine’s distribution in mainland China. The company emphasized this move won’t materially impact its overall operations. Clover is refocusing its efforts on the development of its proprietary respiratory syncytial virus (RSV) vaccine candidate SCB – 1019.
RSV Vaccine Development
Clover remains committed to advancing SCB – 1019, including exploring repeat – dose RSV vaccination strategies and combination vaccine development programs. This strategic shift underscores the company’s dedication to innovation in addressing respiratory viral infections.-Fineline Info & Tech